Assyro AI

Purple Book product · Reference 351(a)

Intron A

interferon alfa-2b

351(a)BLA 103132DiscVoluntarily Revoked Merck Sharp & Dohme LLC

At a glance

Not listed

Approved

Reference 351(a)

License type

Disc

Marketing

No

Patents listed

Key dates

  1. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Nov 21, 1995

    31 yr ago

  2. Today

Pharmaceutical detail

Strength

25MIU

Dosage form

Injection

Route

Intralesional, Intramuscular, Subcutaneous

Presentation

Multi-Dose Vial

Center

CDER

License number

0002

Product number

011

Submission type

Supplement

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Taxonomy and ontology

11 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(a)

blaType · 351(a)

application pathway

Section 351(a) Biologic

blaType · 351(a)

product role

Reference or Standalone Biologic

blaType · Reference product

marketing status

Discontinued

marketingStatus · Disc

licensure status

Voluntarily Revoked

licensure · Voluntarily Revoked

dosage form

Injection

dosageForm · Injection

source kind

Monthly Download

sourceKind · monthly_download

patent status

No Patent List Provided

patentListProvided · No patent list

  • Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(a) Biologicmaps to351(a)
  • 351(a)classifiesReference or Standalone Biologic

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.